Published in Support Care Cancer on September 02, 2015
The Cohesive Metastasis Phenotype in Human Prostate Cancer. Biochim Biophys Acta (2016) 0.76
Longitudinal assessment of pain management with the pain management index in cancer outpatients receiving chemotherapy. Support Care Cancer (2016) 0.75
Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer (2017) 0.75
Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS). J Bone Oncol (2016) 0.75
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Support Care Cancer (2017) 0.75
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75
Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore (1994) 16.38
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes (2003) 5.58
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol (2010) 2.80
Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol (2013) 2.43
Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis (2011) 2.16
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. Eur Urol (2014) 1.81
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer (2008) 1.57
Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat (2011) 1.42
Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol (2009) 1.40
The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res (2006) 1.35
Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat (2011) 1.24
Opioids, pain, and fear. Ann Oncol (2007) 1.15
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer (2013) 1.10
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer (2012) 0.99
Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer (2014) 0.94
Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer (2013) 0.86
Treatment of bone metastases before the onset of pain. Int J Clin Oncol (2012) 0.84
Fear of pain in patients with advanced cancer or in patients with chronic noncancer pain. Clin J Pain (2011) 0.84
Assessing analgesic use in patients with advanced cancer: development of a new scale--the Analgesic Quantification Algorithm. Pain Med (2014) 0.81
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol (2012) 0.79
Repeat palliative radiotherapy for painful bone metastases. Lancet Oncol (2013) 0.77
Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Rev Clin Pharmacol (2012) 0.76
Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes (2016) 0.75
A new paradigm or a misrepresentation of current communication research and teaching? Med Educ (2017) 0.75